The study will test an artificial pancreas system’s ability to function outside of a hospital setting. Similar outpatient trials are currently being conducted in Europe.
The artificial pancreas is an external device under development that works by combining a continuous glucose monitor and an insulin pump with computer software that automatically provides the correct amount of insulin.
The development of an artificial pancreas is one of JDRF’s top priorities. JDRF is supporting the Artificial Pancreas Consortium, an international research group that “aims to speed and optimize the process of linking continuous glucose sensors and insulin pumps,” according to a description of the group.
Related Articles on FDA Clearances and Approvals:
Olympus Receives FDA Clearance for Thunderbeat Hand Instruments
JAMA Article Encourages FDA to Return Device Applications Lacking Trial Data on Women
Proposed Bill Would Tighten FDA Oversight of Medical Devices
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
